Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
June-2016 Volume 37 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2016 Volume 37 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway

  • Authors:
    • Mi-Hua Liu
    • Yuan Zhang
    • Jun He
    • Tian-Ping Tan
    • Shao-Jian Wu
    • Dong-Ming Guo
    • Hui He
    • Juan Peng
    • Zhi-Han Tang
    • Zhi-Sheng Jiang
  • View Affiliations / Copyright

    Affiliations: Department of Clinical Laboratory, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Pathology, Mawangdui Hospital, Changsha, Hunan 410016, P.R. China, Laboratory of Clinical Anatomy, University of South China, Hengyang, Hunan 421001, P.R. China, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, University of South China, Hengyang, Hunan 421001, P.R. China
  • Pages: 1661-1668
    |
    Published online on: April 14, 2016
       https://doi.org/10.3892/ijmm.2016.2563
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Doxorubicin (DOX) is an efficient drug used in cancer therapy that also produces reactive oxygen species (ROS) that induces severe cytotoxicity, which limits its clinical application. Hydrogen sulfide (H2S), a novel gasotransmitter, has been shown to exert cardioprotective effects. The present study aimed to determine whether exogenous H2S protects H9c2 cardiac cells against DOX-induced cytotoxicity and whether these protective effects are mediated through the PI3K/Akt/FoxO3a pathway. The H9c2 cardiac cells were exposed to 5 µM DOX for 24 h to establish a model of DOX-induced cardiotoxicity. The results showed that the treatment of H9c2 cardiac cells with sodium hydrosulfide (NaHS) for 30 min prior to DOX exposure markedly attenuated the phosphorylation of Akt and FoxO3a. Notably, pre-treatment of the H9c2 cells with NaHS significantly attenuated the nuclear localization of FoxO3a as well as the apoptosis of H9c2 cells induced by DOX. The treatment of H9c2 cells with N-acetyl-L-cysteine (NAC), a scavenger of ROS, prior to DOX exposure, also markedly increased the phosphorylation of Akt and FoxO3a which was inhibited by DOX alone. Furthermore, pre-treatment with LY294002, a selective inhibitor of PI3K/Akt, reversed the protective effect of H2S against DOX-induced injury of cardiomyocytes, as demonstrated by an increased number of apoptotic cells, a decrease in cell viability and the reduced phosphorylation of Akt and FoxO3a. These findings suggested that exogenous H2S attenuates DOX-induced cytotoxic effects in H9c2 cardiac cells through the PI3K/Akt/FoxO3a pathway.

Introduction

Doxorubicin (DOX) is one of the most widely used anticancer drugs because of its potent therapeutic effects on various types of cancer, including leukemia, lymphoma and breast cancer. However, the clinical use of DOX is limited by severe cardiotoxicity, which may lead to dilated cardiomyopathy and congestive heart failure (1). The production of reactive oxygen species (ROS) is involved in the toxic effect elicited by DOX on cardiomyocytes and endothelial cells, and in the promotion of endothelial dysfunction (2) and apoptosis (3). A number of pharmacological interventions have been suggested as therapies to protect against DOX-induced cardiotoxicity.

Hydrogen sulfide (H2S) is considered a toxic gas, and has been classified as the third gasotransmitter, together with nitric oxide and carbon monoxide, and exerts various effects on the cardiovascular system (4). Previous findings have shown that H2S protects the heart from myocardial ischemia-reperfusion (IR) injury (5). In a previous study, it was demonstrated that the increased generation of endogenous H2S in the early reperfusion phase has an important function in ischemic pre-conditioning-elicited protection in isolated hearts (6).

The forkhead box class O (FoxO) subfamily of forkhead transcription factors comprises the members FoxO1, FoxO3a and FoxO4, which are downstream targets of Akt (7). FoxO3a is involved in the regulation of various cell processes, including proliferation and apoptosis, as well as protection against oxidative stress and metabolism (8). A model of β-amyloid-induced neuron death was used to demonstrate that FoxO3a is activated, translocates to the nucleus, and subsequently mediates neuron death through Bim (9). In neonatal rat ventricular myocytes (NRVMs), hyperglycemia was demonstrated to markedly enhance the apoptosis of NRVMs through the trans-location of FoxO3a to the nucleus, and the resultant enhanced transcriptional activity of FoxO3a (10). Li et al found that the PI3K/Akt/FoxO3a pathway is involved in neuronal apoptosis in the brain of a developing rat (11). In a previous study, it was demonstrated that resveratrol protects PC12 cells against high glucose-induced oxidative stress and apoptosis through the activation of the PI3K/Akt/FoxO3a signaling pathway (12). In addition, sodium tanshinone IIA sulfonate (13) and bromelain (14) have been found to protect rat hearts against IR injury through the activation of the PI3K/Akt/FoxO3a pathway. Therefore, we hypothesized that the PI3K/Akt/FoxO3a pathway may be involved in the protective effect of exogenous H2S against DOX-induced cardiotoxicity in H9c2 cardiac cells.

To examine this hypothesis, H9c2 cells were treated with 5 µM DOX in the present study to establish a model of chemotherapy-induced cardiotoxicity as previously described (15). Subsequently, we examined: i) the effect of DOX on the phosphorylation of Akt and FoxO3a; ii) the effect of exogenous H2S on the DOX-induced translocation of FoxO3a to the nucleus where it subsequently mediates H9c2 cardiac cell death through Bim; and iii) whether exogenous H2S protects H9c2 cells against DOX-induced cardiotoxicity through the PI3K/Akt/FoxO3a pathway.

Materials and methods

Materials

Methyl thiazolyl tetrazolium (MTT), Hoechst 33258, 2′,7′-dichlorofluorescein diacetate (DCFH-DA), DOX, sodium hydrosulfide (NaHS), and N-acetyl-L-cysteine (NAC) were purchased from Sigma-Aldrich (St. Louis, MO, USA). LY294002 was purchased from Calbiochem (Billerica, MA, USA). Cell culture medium components were purchased from Thermo Fisher Scientific (Waltham, MA, USA) unless otherwise noted. The H9c2 cardiac myocytes were obtained from the Shanghai Cell Library of China [originally from the American Type Culture Collection (ATCC); Manassas, VA, USA].

Cell culture

The H9c2 cardiac cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 µg/ml streptomycin (Life Technologies, Carlsbad, CA, USA) and 100 U/ml penicillin-streptomycin (Life Technologies) in a humidified 5% CO2 atmosphere at 37°C. The H9c2 cardiac myocytes were passaged every 2 days. Subsequently, they were seeded at a density of 2×106 cells/dish in 100-mm dishes with 10% calf serum, incubated for 24 h and then, the medium was replaced with 0.5% FBS DMEM for 24-h serum starvation. To determine the degree of apoptosis, the H9c2 cardiac myocytes were treated with NaHS (100 µM) for 30 min or NAC (1,000 µM) for 60 min, followed by exposure to DOX for 24 h. In some experiments, the H9c2 cells were treated with LY294002 (50 µM) prior to NaHS stimulation.

MTT assay

The MTT assay is a standard method used to assess cell viability. Prior to each experiment, the H9c2 cardiac myocytes (5×102 cells/well) were seeded in 96-well microtiter plates. After incubation with the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 (50 µM) and/or NaHS for 30 min, the cells were exposed to 5 µM DOX for a further 24 h. Subsequently, 10 µl MTT solution was added to each well, and the plates were incubated for 4 h at 37°C. The absorbance was measured at 470 nm using a SpectraMax 190 Absorbance Microplate Reader (Molecular Devices LLC, Sunnyvale, CA, USA) and used to calculate the relative ratio of cell viability. Three independent experiments were performed for each experimental condition.

Assessment of H9c2 cell apoptosis

The analysis of apoptosis was performed by fluorescence microscopy with the chromatin dye Hoechst 33258. After various treatments, the cells were fixed in ice-cold 4% paraformaldehyde dissolved in phosphate-buffered saline (PBS) at room temperature for 20 min. Non-specific binding was blocked using 5% normal goat serum in 0.01 M PBS containing 0.3% Triton X-100 (PBS+T). The cells were washed twice with PBS and incubated with 10 µg/ml Hoechst 33258 for 15 min at room temperature in the dark. The cells were visualized under a fluorescence microscope (BX50-FLA; Olympus, Tokyo, Japan). Apoptotic cells exhibited condensed, fractured or distorted nuclei, whereas viable cells exhibited normal nuclear size and uniform fluorescence.

Measurement of intracellular ROS levels

The determination of intracellular ROS levels was performed by measuring the level of a fluorescent product formed by the oxidation of DCFH-DA. Briefly, the culture medium was plated into 96-well microtiter plates. After various treatments, the cells were washed with PBS 3 times. Following the addition of fresh culture medium, the cells were incubated with DCFH-DA at a final concentration of 10 µmol/l for 30 min at 37°C. The cells were washed again with PBS 3 times and then lysed with 500 µl 90% DMSO and 10% PBS for 10 min at room temperature in the dark. The supernatant (200 µl) was transferred to another 96-well microtiter plate. The fluorescence intensity of the oxidized product, 2′,7′-dichlorofluorescein (DCF), was measured using a Model F-4500 fluorescence spectrophotometer (Hitachi, Tokyo, Japan) at 495 nm (excitation) and 520 nm (emission). The values were expressed as the percentage of fluorescence intensity relative to the control wells.

Western blot analysis

H9c2 cells were treated with 0.1, 1, 5 and 10 µM DOX for 24 h (Fig. 1) and exposed to 5 µM DOX for 3, 6, 12 and 24 h (Fig. 2). The cells were homogenized directly in cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) and phosphatase inhibitor cocktail (Sigma-Aldrich). The lysates were centrifuged at 12000 × g for 10 min at 4°C. The protein concentration was determined with the use of a BCA protein assay kit according to the manufacturer's instructions. For nuclear/cytoplasmic fractionation, the cultured H9c2 cells were fractionated into nuclear and cytoplasmic lysates using a Nuclear and Cytoplasmic Protein Extraction kit (Beyotime Institute of Biotechnology, Shanghai, China) according to the manufacturer's instructions. The extracted proteins were mixed with 5% sodium dodecyl sulfate (SDS)-PAGE sample buffer, boiled at 100°C for 7 min and then separated by electrophoresis on a 10% SDS-polyacrylamide gel. Following electrophoresis, the proteins were transferred to polyvinylidene difluoride membranes (Beyotime Institute of Biotechnology). The membranes were blocked in Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) with 5% non-fat dry milk, for 2 h at room temperature, with rotation. After blocking, the membranes were incubated with the following antibodies: rabbit anti-Akt polyclonal antibody (cat. no. 9272, 1:2,000), rabbit anti-phosphorylated (p-) Akt (Ser 473) monoclonal antibody (cat. no. 4060, 1:2,000), rabbit anti-FoxO3a polyclonal antibody (cat. no. 12829, 1:2,000), rabbit anti-p-FoxO3a (ser 253) polyclonal antibody (cat. no. 9466, 1:1,000) (all from Cell Signaling Technology) and rabbit anti-Bim poly-clonal antibody (ab32158, 1:200; Abcam, Cambridge, MA, USA). The membranes were then incubated in 5% milk or bovine serum albumin overnight at 4°C. The primary antibody was removed by washing the membranes 3 times in TBS-T, and subsequently incubating the membranes for 2 h with the appropriate horseradish peroxidase-conjugated secondary antibodies. After washing the membranes 3 times in TBS-T, the antigen-antibody bands were detected using an enhanced chemiluminescence reagent kit and quantified using a densitometry program. The data from the western blot analysis of p-Akt and p-FoxO3a were presented as a ratio of the p-forms to their total forms, respectively. The immunoblot of Bim was corrected to the bands of GAPDH.

Figure 1

Doxorubicin (DOX) decreases the expression of phosphorylated (p)-Akt and p-FoxO3a in H9c2 cells in a dose-dependent manner. H9c2 cells were exposed to DOX at different concentrations for 24 h. (A and B) Phosphorylation of Akt and FoxO3a was determined using western blot analysis. (C and D) Relative levels of p-FoxO3a versus total FoxO3a, and p-Akt versus total Akt in each sample as determined by blot densitometry. Data are shown as the means ± SEM (n=3). *P<0.05, **P<0.01 compared with the control group.

Figure 2

Doxorubicin (DOX) decreases the expression of phosphorylated (p)-Akt and p-FoxO3a in H9c2 cells in a time-dependent manner. H9c2 cells were exposed to 5 µM DOX for the indicated time periods. (A and B) Phosphorylation of Akt and FoxO3a was determined using western blot analysis. (C and D) Relative levels of p-FoxO3a versus total FoxO3a, and p-Akt versus total Akt in each sample as determined by blot densitometry. Data are shown as the means ± SEM (n=3). *P<0.05, **P<0.01 compared with the control group.

Statistical analysis

The results are presented as the means ± SEM. Statistical analysis was performed using the Student's t-test or analysis of variance (ANOVA) with SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). In all cases, P<0.05 was considered to indicate a statistically significant difference.

Results

DOX decreases the phosphorylation of Akt and FoxO3a in H9c2 cells

To investigate the role of the PI3K/Akt/FoxO3a pathway in DOX-induced cytotoxicity, we investigated the phosphorylation of Akt and FoxO3a in the H9c2 cells following exposure to DOX. The H9c2 cells were treated with DOX at different concentrations for different time periods, and the effect on the phosphorylation of Akt and FoxO3a was determined using western blot analysis. Figs. 1 and 2 show that DOX decreased the phosphorylation of Akt and FoxO3a in the H9c2 cells in a concentration- and time-dependent manner. DOX inhibited the phosphorylation of Akt and FoxO3a in the H9c2 cells at a concentration of 1 µM and the maximal effect was reached at a concentration of 10 µM (Fig. 1). Fig. 2 shows that 5 µM DOX induced a significant decrease in the levels of p-Akt and p-FoxO3a at 6 and 12 h, and it almost completely abolished the phosphorylation of Akt and FoxO3a at 24 h in the H9c2 cells.

Exogenous H2S ameliorates the DOX-induced decrease in the levels of p-Akt and p-FoxO3a in H9c2 cells

To determine whether the cytoprotective effect of H2S against DOX-induced toxicity was associated with the PI3K/Akt/FoxO3a pathway in H9c2 cells, we examined the effect of NaHS on the expression of p-Akt and p-FoxO3a. The results showed that treating the H9c2 cells with 100 µM NaHS (a donor of H2S) for 30 min prior to exposure to 5 µM DOX for 24 h significantly increased the phosphorylation of Akt and FoxO3a (Fig. 3). Furthermore, NaHS treatment alone also significantly increased the levels of p-Akt and p-FoxO3a compared with the DOX-treated groups. The total Akt and FoxO3a levels remained unchanged among the four groups. These results suggested that the PI3K/Akt/FoxO3a pathway was involved in the protective effect of H2S.

Figure 3

Effect of hydrogen sulfide (H2S) on the doxorubicin (DOX)-induced decrease in the expression of phosphorylated (p)-Akt and p-FoxO3a in H9c2 cells. H9c2 cells were exposed to 5 µM DOX for 24 h and then cells were treated with 100 µM sodium hydrosulfide (NaHS) for 30 min prior to DOX exposure or untreated. (A and B) Phosphorylation of Akt and FoxO3a was examined using western blot analysis. (C and D) Relative levels of p-FoxO3a versus total FoxO3a and p-Akt versus total Akt in each sample as determined by blot densitometry. Data are shown as the means ± SEM (n=3). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group.

NAC ameliorates the DOX-induced decrease in the levels of p-Akt and p-FoxO3a in H9c2 cells

The H9c2 cells were treated with 1,000 µM NAC (ROS scavenger) for 60 min prior to exposure to 5 µM DOX for 24 h, to confirm whether the protective effect of H2S on the DOX-induced decrease in p-Akt and p-FoxO3a is associated with antioxidation. As shown in Fig. 4, the pretreatment of the H9c2 cells with NAC markedly increased the expression of p-Akt and p-FoxO3a and this was similar to the protective effect observed with NaHS pre-treatment. The total Akt and FoxO3a levels remained unchanged in the four groups. The results revealed that an antioxidant effect contributed to the protective effect of H2S against DOX-induced injuries.

Figure 4

Effect of N-acetyl-L-cysteine (NAC) on the doxorubicin (DOX)-induced decrease in the expression of phosphorylated (p)-Akt and p-FoxO3a in H9c2 cells. H9c2 cells were exposed to 5 µM DOX for 24 h and then the cells were either treated with 1,000 µM NAC for 60 min or untreated. (A and B) Western blot analysis was applied to detect changes in the phosphorylation of Akt and FoxO3a. (C and D) Relative levels of p-FoxO3a versus total FoxO3a, and p-Akt versus total Akt in each sample as determined by blot densitometry. Data are shown as the means ± SEM (n=3). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group.

Exogenous H2S induces Akt and FoxO3a phosphorylation through the PI3K/Akt pathway in H9c2 cells

To investigate the role of the PI3K/Akt pathway in the protective effects of H2S, the H9c2 cells were treated with the PI3K inhibitor LY294002 prior to exposure to NaHS plus DOX. The activation of Akt and FoxO3a was determined as described above. LY294002 abolished the stimulation of p-Akt and p-FoxO3a in the presence of NaHS (Fig. 5), but elicited no effect on the expression levels of total Akt and FoxO3a. These results suggested that the PI3K/Akt/FoxO3a pathway was involved in the protective effect of H2S.

Figure 5

LY294002 inhibits the effect of hydrogen sulphide (H2S) on Akt and FoxO3a phosphorylation in H9c2 cells. H9c2 cells were exposed to 5 µM doxorubicin (DOX) for 24 h and were untreated or treated with 100 µM sodium hydrosulfide (NaHS) and/or 50 µM LY294002 for 30 min prior to DOX exposure. (A and B) Phosphorylation of Akt and FoxO3a was determined using western blot analysis. (C and D) Relative levels of p-FoxO3a versus total FoxO3a, and p-Akt versus total Akt in each sample as determined by blot densitometry. Data are shown as the means ± SEM (n=3). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group; &P<0.05, compared with the NaHS+DOX group. LY, LY294002.

DOX enhances the nuclear localization of FoxO3a in H9c2 cells whereas H2S blocks the effect of DOX

The transcription factor FoxO3a functions through its phosphorylation and subcellular localization. The phosphorylation of FoxO3a by Akt causes it to localize in the cytoplasm and inhibit the functions of FoxO3a, including pro-apoptotic effects (25). By contrast, dephosphorylation of this protein promotes the translocation of FoxO3a to the nucleus and triggers apoptosis. To investigate the effects of H2S and DOX on FoxO3a, we studied the subcellular localization of FoxO3a following exposure to these reagents. Nuclear and cytosolic proteins from H9c2 cells were extracted, and the subcellular localization of FoxO3a was determined. Fig. 6 shows that DOX enhanced the nuclear localization of FoxO3a in the H9c2 cells, whereas NaHS blocked the effect of DOX. Co-treatment with the PI3K inhibitor, LY294002, abolished the protective effect of NaHS.

Figure 6

LY294002 inhibits the effect of hydrogen sulphide (H2S) on FoxO3a nuclear translocation. H9c2 cells were treated with 5 µM doxorubicin (DOX) for 24 h and either untreated or pretreated with 100 µM sodium hydrosulfide (NaHS) and/or 50 µM LY294002 for 30 min prior to DOX exposure. (A and B) Protein levels of nuclear and cytosolic FoxO3a were determined using western blot analysis. (C and D) Quantification of the nuclear and cytosolic protein levels of FoxO3a. Data are shown as the means ± SEM (n=3). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group; &P<0.05, compared with the NaHS+DOX group. LY, LY294002.

Exogenous H2S downregulates Bim expression through the PI3K/Akt-dependent signaling pathway

A significant down-regulation of Bim protein was observed in the NaHS + DOX group compared with the DOX-treated group. Furthermore, co-treatment with LY294002 increased Bim protein expression compared with the control group (Fig. 7). These results indicated that pre-treatment with NaHS downregulated the expression of Bim through a PI3K/Akt-dependent signaling pathway.

Figure 7

LY294002 inhibits the effect of hydrogen sulfide (H2S) on doxorubicin (DOX)-induced Bim expression. H9c2 cells were exposed to 5 µM DOX for 24 h and were either untreated or treated with 100 µM sodium hydrosulfide (NaHS) and/or 50 µM LY294002 for 30 min prior to DOX exposure. (A) Bim protein expression was determined using western blot analysis. (B) Relative levels of Bim in each sample as determined by blot densitometry. Data are shown as the means ± SEM (n=3). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group; &P<0.05, compared with the NaHS + DOX group. LY, LY294002.

Exogenous H2S inhibits DOX-induced cytotoxicity

Fig. 8A shows that the exposure of the H9c2 cells to DOX for 24 h induced marked cytotoxicity, leading to a decrease in cell viability. However, cell pre-treatment with 100 µM NaHS for 30 min prior to DOX exposure significantly attenuated the degree of DOX-induced cytotoxicity, as demonstrated by an increase in cell viability. The preceding results (Figs. 3 and 5) showed that H2S attenuated the DOX-induced decrease in p-Akt in the H9c2 cells. Thus, we aimed to confirm whether the PI3K/Akt signaling pathway is involved in the protective effect of H2S. The treatment of the H9c2 cells with LY294002 and NaHS for 30 min prior to DOX exposure for 24 h abolished the protective effect of H2S, leading to an decrease in cell viability (Fig. 8A). NaHS alone did not alter the viability of the H9c2 cells. These findings suggested that H2S exerts a protective effect against DOX-induced cytotoxicity, which may occur through the PI3K/Akt signaling pathway.

Figure 8

Exogenous hydrogen sulfide (H2S) protects H9c2 cells against doxorubicin (DOX)-induced injuries. (A) Cell viability was measured using the MTT assay. (B) Cell apoptosis was measured using Hoechst 33258 nuclear staining. Data are shown as the means ± SEM (n=3). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group; &P<0.05, compared with the sodium hydrosulfide (NaHS) + DOX group. LY, LY294002.

Exogenous H2S reduces DOX-induced apoptosis in H9c2 cells

The effects of H2S on DOX-induced apoptosis were observed. Fig. 8B shows that the apoptotic rate of the H9c2 cells exposed to 5 µM of DOX for 24 h increased significantly. However, cell pre-treatment with 100 µM NaHS for 30 min prior to DOX exposure markedly decreased the DOX-induced increase in the apoptotic rate. To ascertain whether the PI3K/Akt signaling pathway is involved in apoptosis induced by DOX, the H9c2 cells were treated with LY294002 prior to exposure to NaHS plus DOX. The results revealed that pretreatment with LY294002 abolished the protective effect of H2S. NaHS alone did not markedly alter the percentage of apoptotic H9c2 cells. These data strongly suggest that H2S protects DOX-exposed H9c2 cells against apoptosis and this may occur through the PI3K/Akt signaling pathway.

Exogenous H2S reduces DOX-induced oxidative stress in H9c2 cells

The effect of H2S on the DOX-induced production of ROS was investigated to elucidate whether the antioxidant activity of H2S affords a cytoprotective effect against DOX-induced cardiotoxicity. Fig. 9 shows that the exposure of H9c2 cells to 5 µM DOX evidently enhanced the generation of intracellular ROS. However, NaHS pre-conditioning for 30 min markedly attenuated the DOX-elicited generation of ROS. Notably, pre-treatment with LY294002 abolished the protective effect of H2S. However, NaHS alone did not alter the basal levels of intracellular ROS.

Figure 9

Exogenous hydrogen sulfide (H2S) reduces doxorubicin (DOX)-induced ROS production in H9c2 cells. Intracellular ROS levels were determined by measuring the fluorescent intensity of DCF oxidized from DCFH-DA using a fluorescence microplate reader. Data are shown as the means ± SEM (n=5). *P<0.05, compared with the control group; #P<0.05, compared with the DOX-treated group; &P<0.05, compared with the sodium hydrosulfide (NaHS) + DOX group. LY, LY294002.

Discussion

DOX is one of the most widely used and successful antitumor drugs, although the clinical use of DOX is limited by cumulative and dose-dependent cardiotoxic effects. With an increasing population of cancer survivors, there is a growing need to develop preventive strategies and effective therapies against DOX-induced cardiotoxicity, and particularly, late-onset cardio-myopathy. Although the cardiotoxic effects of DOX have been previously examined, the underlying mechanisms responsible for these effects remain to be elucidated. Mounting evidence supports the hypothesis that free radical-induced oxidative stress, which leads to cardiomyocyte death by apoptosis and necrosis, is a key contributor to DOX-induced cardiotoxicity (16).

Previous findings have demonstrated that exogenous H2S offers protection against DOX-induced cardiotoxicity through antoixidant effects and the downregulation of inflammatory responses (15,17,18). Guo et al have demonstrated that exogenous H2S attenuates DOX-induced inflammation and cytotoxicity through the inhibition of the p38 MAPK/NF-κB pathway in H9c2 cells (15). H2S also attenuates DOX-induced cardiotoxicity through the inhibition of endoplasmic reticulum stress in H9c2 cells (17). Su et al have demonstrated that the downregulation of endogenously generated H2S is probably involved in the pathogenesis of DOX-induced cardiomyopathy, as H2S reduces lipid peroxidation, increases the activity of antioxidant enzyme systems and inhibits oxidative stress-induced injury (18).

Erythropoietin has been found to protect the myocardium against DOX-induced impairment of heart function and inhibits the apoptosis of cardiomyocytes by activating the PI3K/Akt cell-survival pathway (19). In addition, neureg-ulin-1 (20), tanshinone IIA (21), and urotensin II (22) have been demonstrated to prevent the apoptosis of cardiomyocytes exposed to DOX, partly through the Akt signaling pathways. Thus, these agents may promote cell survival and exert cardioprotective effects. FoxO3a is regulated by the PI3K/Akt pathway and plays an important role in mediating the cytotoxic effects of DOX (23). It has also been demonstrated that in the presence of serum and growth factors, the survival kinase Akt is phosphorylated, which in turn phosphorylates FoxO transcription factors, thereby leading to nuclear exclusion, cytoplasmic retention and the inactivation of FoxO transcription factors (24). Conversely, oxidative stress has been shown to induce the re-localization of FoxO transcription factors from the cytoplasm to the nucleus and activate the target genes of FoxO transcription factors, including the pro-apoptotic gene Bim, with subsequent cell apoptosis (25).

The roles of FoxO3a in oxidative stress-induced cardio-toxicity have received attention. Cardiac microvascular endothelial cells (CMECs) are some of the predominant cells that are immediately damaged after myocardial I/R injury. High glucose (26) and hypoxia (27) have been observed to reduce the phosphorylation of Akt and FoxO3a, induce FoxO3a activation, and lead to ROS production and apoptosis in CMECs. Wang et al reported that venlafaxine protects PC12 cells against corticosterone-induced cell death by modulating the activity of the PI3K/Akt/FoxO3a pathway (7). Simvastatin inhibits rapamycin-induced dysfunction and apoptosis of CMECs, probably through the activation of the PI3K/Akt/FoxO3a signaling pathway (28). Furthermore, erythropoietin activates the PI3K/Akt/FoxO3a signaling pathway and protects neurons from 6-hydroxydopamine (6-OHDA)-induced apoptosis (29). In addition, sodium tanshinone IIA sulfonate (13) and bromelain (14) have been demonstrated to inhibit the FoxO3a pathway and apoptosis of cardiomyocytes. In the present study, we have demonstrated that a statistically significant reduction in the phosphorylation of Akt and FoxO3a protein was observed in the DOX-treated H9c2 cells. The data suggest that the PI3K/Akt/FoxO3a signaling pathway is important in DOX-induced cytoxicity in cardiomyocytes.

To elucidate the potential protective effects of H2S against DOX-induced cardiotoxicity as well as the mechanisms responsible for these effects, we observed the effect of NaHS on the phosphorylation of Akt and FoxO3a protein induced by DOX exposure. The findings of the present study show that the treatment of H9c2 cells with NaHS significantly prevented the DOX-induced reduction in the levels of p-Akt and p-FoxO3a, and this was accompanied by an increase in cell viability, indicating that the PI3K/Akt/FoxO3a pathway may be involved in the protective effects of exogenous H2S against DOX-induced cardiotoxicity.

Notably, the results of the present study provide novel evidence that an interaction between ROS and FoxO3a exists in DOX-exposed H9c2 cells, because H2S attenuated the DOX-induced reduction in p-Akt and p-FoxO3a levels. Similar to exogenous H2S, the treatment of H9c2 cells with NAC (ROS scavenger) prior to DOX exposure attenuated the phosphorylation of Akt and FoxO3a. These results indicated that targeting the interaction that occurs between ROS and FoxO3a in DOX-induced cardiotoxicity may aid in the treatment and prevention of cardiac injury. Another important novel finding of this study was that exogenous H2S protects against DOX-induced cardiotoxicity by activating the PI3K/Akt/FoxO3a pathway in H9c2 cells. The findings of the present study support this hypothesis. The treatment of H9c2 cells with NaHS (a donor of H2S) prior to DOX exposure significantly ameliorated the reduction in p-Akt and p-FoxO3a, attenuated the nuclear localization of FoxO3a and the DOX-induced apoptosis of H9c2 cells, and exerted an inhibitory effect on Bim expression. In addition, pre-treatment with LY294002, a selective inhibitor of PI3K/Akt, reversed the protective effect of H2S on DOX-induced cardiotoxicity, as demonstrated by an increase in the number of apoptotic cells, a reduction in cell viability and the phosphorylation of Akt and FoxO3a, as well as a simultaneous increase in Bim expression. Therefore, our results suggest that the protective effects of H2S on FoxO3a nuclear translocation and Bim expression are mediated by the PI3K/Akt pathway.

In conclusion, to the best of our knowledge, the present study has demonstrated for the first time, that FoxO3a plays a central role in the DOX-induced apoptosis of H9c2 cells. Furthermore, data from the present study have revealed that H2S protects H9c2 cardiomyocytes against DOX-induced cytotoxicity through the activation of the PI3K/Akt/FoxO3a pathway. To the best of our knowledge, this is the first study to show that H2S is capable of acting on the PI3K/Akt/FoxO3a pathway to enhance the survival of cardiomyocytes, thereby suggesting that the FoxO3a pathway may be a novel therapeutic target in cardiovascular disease.

Acknowledgments

The present study was supported by grants from the National Natural Science Foundation of China (81470435, Z.-S.J.) and the Graduate student research innovation project of Hunan province (CX2013B397, M.-H.L.).

References

1 

Magnano LC, Martínez Cibrian N, Andrade González X and Bosch X: Cardiac complications of chemotherapy: role of prevention. Curr Treat Options Cardiovasc Med. 16:3122014. View Article : Google Scholar : PubMed/NCBI

2 

Truong J, Yan AT, Cramarossa G and Chan KK: Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol. 30:869–878. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Spagnuolo RD, Recalcati S, Tacchini L and Cairo G: Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity. Br J Pharmacol. 163:299–312. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Zhang Y, Tang ZH, Ren Z, Qu SL, Liu MH, Liu LS and Jiang ZS: Hydrogen sulfide, the next potent preventive and therapeutic agent in aging and age-associated diseases. Mol Cell Biol. 33:1104–1113. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Osipov RM, Robich MP, Feng J, Liu Y, Clements RT, Glazer HP, Sodha NR, Szabo C, Bianchi C and Sellke FW: Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection. J Cardiovasc Pharmacol. 54:287–297. 2009. View Article : Google Scholar : PubMed/NCBI

6 

Huang YE, Tang ZH, Xie W, Shen XT, Liu MH, Peng XP, Zhao ZZ, Nie DB, Liu LS and Jiang ZS: Endogenous hydrogen sulfide mediates the cardioprotection induced by ischemic post-conditioning in the early reperfusion phase. Exp Ther Med. 4:1117–1123. 2012.PubMed/NCBI

7 

Wang H, Zhou X, Huang J, Mu N, Guo Z, Wen Q, Wang R, Chen S, Feng ZP and Zheng W: The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone-induced cell death in PC12 cells. Psychopharmacology (Berl). 228:129–141. 2013. View Article : Google Scholar

8 

van der Vos KE and Coffer PJ: The extending network of FOXO transcriptional target genes. Antioxid Redox Signal. 14:579–592. 2011. View Article : Google Scholar

9 

Sanphui P and Biswas SC: FoxO3a is activated and executes neuron death via Bim in response to β-amyloid. Cell Death Dis. 4:e6252013. View Article : Google Scholar

10 

Bao W, Pan F, Chen L, Su G, Gao X, Li Y, Sun Q, Sun J, He K and Song H: The PI3K/AKT pathway and FOXO3a transcription factor mediate high glucose-induced apoptosis in neonatal rat ventricular myocytes. Iran Red Crescent Med J. 16:e149142014. View Article : Google Scholar : PubMed/NCBI

11 

Li D, Qu Y, Mao M, Zhang X, Li J, Ferriero D and Mu D: Involvement of the PTEN-AKT-FOXO3a pathway in neuronal apoptosis in developing rat brain after hypoxia-ischemia. J Cereb Blood Flow Metab. 29:1903–1913. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Liu MH, Yuan C, He J, Tan TP, Wu SJ, Fu HY, Liu J, Yu S, Chen YD, Le QF, et al: Resveratrol protects PC12 cells from high glucose-induced neurotoxicity via PI3K/Akt/FoxO3a pathway. Cell Mol Neurobiol. 35:513–522. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Zhang MQ, Zheng YL, Chen H, Tu JF, Shen Y, Guo JP, Yang XH, Yuan SR, Chen LZ, Chai JJ, et al: Sodium tanshinone IIA sulfonate protects rat myocardium against ischemia-reperfusion injury via activation of PI3K/Akt/FOXO3A/Bim pathway. Acta Pharmacol Sin. 34:1386–1396. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Juhasz B, Thirunavukkarasu M, Pant R, Zhan L, Penumathsa SV, Secor ER Jr, Srivastava S, Raychaudhuri U, Menon VP, Otani H, et al: Bromelain induces cardioprotection against ischemia-reperfusion injury through Akt/FOXO pathway in rat myocardium. Am J Physiol Heart Circ Physiol. 294:H1365–H1370. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D, Chen P, Chen G, Xu W and Feng J: Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells. Cell Physiol Biochem. 32:1668–1680. 2013.

16 

Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, Arcari A, Piscopo G, Cipresso C, Monti MG, et al: Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 16:358–366. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Wang XY, Yang CT, Zheng DD, Mo LQ, Lan AP, Yang ZL, Hu F, Chen PX, Liao XX and Feng JQ: Hydrogen sulfide protects H9c2 cells against doxorubicin-induced cardiotoxicity through inhibition of endoplasmic reticulum stress. Mol Cell Biochem. 363:419–426. 2012. View Article : Google Scholar

18 

Su YW, Liang C, Jin HF, Tang XY, Han W, Chai LJ, Zhang CY, Geng B, Tang CS and Du JB: Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. Circ J. 73:741–749. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Kim KH, Oudit GY and Backx PH: Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther. 324:160–169. 2008. View Article : Google Scholar

20 

An T, Zhang Y, Huang Y, Zhang R, Yin S, Guo X, Wang Y, Zou C, Wei B, Lv R, et al: Neuregulin-1 protects against doxorubicin-induced apoptosis in cardiomyocytes through an Akt-dependent pathway. Physiol Res. 62:379–385. 2013.PubMed/NCBI

21 

Hong HJ, Liu JC, Chen PY, Chen JJ, Chan P and Cheng TH: Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. Int J Cardiol. 157:174–179. 2012. View Article : Google Scholar

22 

Chen YL, Loh SH, Chen JJ and Tsai CS: Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK. Eur J Pharmacol. 680:88–94. 2012. View Article : Google Scholar : PubMed/NCBI

23 

Ho KK, McGuire VA, Koo CY, Muir KW, de Olano N, Maifoshie E, Kelly DJ, McGovern UB, Monteiro LJ, Gomes AR, et al: Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem. 287:1545–1555. 2012. View Article : Google Scholar :

24 

Wang Y, Zhou Y and Graves DT: FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014:9253502014.PubMed/NCBI

25 

Storz P: Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal. 14:593–605. 2011. View Article : Google Scholar :

26 

Peng C, Ma J, Gao X, Tian P, Li W and Zhang L: High glucose induced oxidative stress and apoptosis in cardiac microvascular endothelial cells are regulated by FoxO3a. PLoS One. 8:e797392013. View Article : Google Scholar : PubMed/NCBI

27 

Zhang S, Zhao Y, Xu M, Yu L, Zhao Y, Chen J, Yuan Y, Zheng Q and Niu X: FoxO3a modulates hypoxia stress induced oxidative stress and apoptosis in cardiac microvascular endothelial cells. PLoS One. 8:e803422013. View Article : Google Scholar : PubMed/NCBI

28 

Pan Q, Xie X, Guo Y and Wang H: Simvastatin promotes cardiac microvascular endothelial cells proliferation, migration and survival by phosphorylation of p70 S6K and FoxO3a. Cell Biol Int. 38:599–609. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Jia Y, Mo SJ, Feng QQ, Zhan ML, OuYang LS, Chen JC, Ma YX, Wu JJ and Lei WL: EPO-dependent activation of PI3K/Akt/FoxO3a signalling mediates neuroprotection in in vitro and in vivo models of Parkinson's disease. J Mol Neurosci. 53:117–124. 2014. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Liu M, Zhang Y, He J, Tan T, Wu S, Guo D, He H, Peng J, Tang Z, Jiang Z, Jiang Z, et al: Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway. Int J Mol Med 37: 1661-1668, 2016.
APA
Liu, M., Zhang, Y., He, J., Tan, T., Wu, S., Guo, D. ... Jiang, Z. (2016). Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway. International Journal of Molecular Medicine, 37, 1661-1668. https://doi.org/10.3892/ijmm.2016.2563
MLA
Liu, M., Zhang, Y., He, J., Tan, T., Wu, S., Guo, D., He, H., Peng, J., Tang, Z., Jiang, Z."Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway". International Journal of Molecular Medicine 37.6 (2016): 1661-1668.
Chicago
Liu, M., Zhang, Y., He, J., Tan, T., Wu, S., Guo, D., He, H., Peng, J., Tang, Z., Jiang, Z."Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway". International Journal of Molecular Medicine 37, no. 6 (2016): 1661-1668. https://doi.org/10.3892/ijmm.2016.2563
Copy and paste a formatted citation
x
Spandidos Publications style
Liu M, Zhang Y, He J, Tan T, Wu S, Guo D, He H, Peng J, Tang Z, Jiang Z, Jiang Z, et al: Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway. Int J Mol Med 37: 1661-1668, 2016.
APA
Liu, M., Zhang, Y., He, J., Tan, T., Wu, S., Guo, D. ... Jiang, Z. (2016). Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway. International Journal of Molecular Medicine, 37, 1661-1668. https://doi.org/10.3892/ijmm.2016.2563
MLA
Liu, M., Zhang, Y., He, J., Tan, T., Wu, S., Guo, D., He, H., Peng, J., Tang, Z., Jiang, Z."Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway". International Journal of Molecular Medicine 37.6 (2016): 1661-1668.
Chicago
Liu, M., Zhang, Y., He, J., Tan, T., Wu, S., Guo, D., He, H., Peng, J., Tang, Z., Jiang, Z."Hydrogen sulfide protects H9c2 cardiac cells against doxorubicin-induced cytotoxicity through the PI3K/Akt/FoxO3a pathway". International Journal of Molecular Medicine 37, no. 6 (2016): 1661-1668. https://doi.org/10.3892/ijmm.2016.2563
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team